Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars Oct 1, 2025 07:30AM
Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe Apr 28, 2025 04:00AM
Biocon Biologics recieves FDA approval for Jobevne Apr 10, 2025 08:41AM
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States Feb 24, 2025 07:00AM
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis Feb 6, 2025 08:00AM


Jan 9, 2025 07:51AM Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
May 21, 2024 08:00AM Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market
Feb 29, 2024 09:56AM Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
Sep 6, 2023 07:00AM Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule
Jul 24, 2023 06:30AM Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
Jul 3, 2023 12:40PM AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
Mar 9, 2020 08:05AM Mylan (MYL) Announces U.S. FDA Accepts BLA Proposed Biosimilar Bevacizumab for Review
Mar 9, 2020 08:00AM U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review